Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

GlobeNewswireMar 6 06:52

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

YolowireMar 6 04:32

J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Raises Target Price to $43

Futu NewsMar 4 00:32 · Ratings

Agios Pharmaceuticals Price Target Maintained With a $58.00/Share by HC Wainwright & Co.

Dow JonesFeb 24 20:48 · Ratings

Agios Pharmaceuticals Analyst Ratings

BenzingaFeb 24 20:33 · Ratings

H.C. Wainwright Initiates Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $58

Futu NewsFeb 24 19:31 · Ratings